News

  1. Nashville lab ramps up xylazine testing increasingly detected in drug overdoses

    The Biden Administration recently designated the fentanyl-xylazine combination as an emerging national threat. Aegis Sciences Corporation in Nashville…

    The Biden Administration recently designated the fentanyl-xylazine combination as an emerging national threat. Aegis Sciences Corporation in Nashville has been on the forefront of testing for the deadly compound. Dr. Josh Schrecker, senior director of clinical affairs talked with NewsChannel 5 about how providers utilize test results. Early identification of these compounds is key to appropriate treatment…

  2. Regina Sweeney, Aegis Sciences Corporation Wins Bronze Stevie® Award in 2023 Stevie Awards for Sales & Customer Service

    NASHVILLE, Tenn., March 6, 2023 – Regina Sweeney, Vice President of Client Relations, Aegis Sciences Corporation has been presented with a Bronze Stevie®…

    NASHVILLE, Tenn., March 6, 2023 – Regina Sweeney, Vice President of Client Relations, Aegis Sciences Corporation has been presented with a Bronze Stevie® Award in the Sales & Customer Service category in the 17th annual Stevie Awards for Sales & Customer Service. The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development and…

  3. Surveillance and Testing to Stem the Tide of the Next Opioid Drug Crisis

    Surveillance and Testing to Stem the Tide of the Next Opioid Drug Crisis

    Aegis recent panelist, Alex J. Krotulski, PhD, released an op-ed that is an exploration into the identification of new and emerging synthetic opioids.

    Aegis recent panelist, Alex J. Krotulski, PhD, released an op-ed that is an exploration into the identification of new and emerging synthetic opioids.

  4. Aegis Sciences Corp Selects Quadax as a Revenue Cycle Management Partner for Their Laboratory Business

    CLEVELAND, Ohio, February 7, 2023 – Quadax, Inc., a leading provider of healthcare revenue cycle management technology and services commenced a strategic…

    CLEVELAND, Ohio, February 7, 2023 – Quadax, Inc., a leading provider of healthcare revenue cycle management technology and services commenced a strategic partnership with Aegis Sciences Corporation, a national laboratory servicing healthcare providers and pharmaceutical, governmental, and athletic organizations, to manage revenue cycle management for their extensive laboratory services offering. With…

  5. Why Enhanced Confirmation Testing Is Critical To Understanding Nashville’s Drug Landscape and Improving Public Health

    Why Enhanced Confirmation Testing Is Critical To Understanding Nashville’s Drug Landscape and Improving Public Health

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he touches on Nashville's Drug Landscape, the Role Testing Plays…

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he touches on Nashville's Drug Landscape, the Role Testing Plays in Identifying Drugs in Patients' Systems, and the Top Illicit Substances Found in Tennessee.

  6. CDC publication acknowledges Aegis Sciences and Walgreens for their work

    The Centers for Disease Control publishes two Morbidity and Mortality Weekly Reports utilizing spike-protein target failure/performance, SGTF/rSGTP, as…

    The Centers for Disease Control publishes two Morbidity and Mortality Weekly Reports utilizing spike-protein target failure/performance, SGTF/rSGTP, as a proxy to track emerging SARS-CoV-2 variants and vaccine effectiveness against Omicron sublineages related to BA.5 and XBB/XBB.1.5. Acknowledging Aegis Sciences and Walgreens for their work published previously in PLOS1, SGTF/rSTGP monitoring proves…

  7. Aegis Sciences Corporation Study Shows Widespread Distribution of Xylazine

    NASHVILLE, Tenn. (Jan. 23, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, has published a Journal of Addiction Medicine…

    NASHVILLE, Tenn. (Jan. 23, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, has published a Journal of Addiction Medicine study finding a widespread presence of the animal tranquilizer xylazine across the U.S. Previously, the use of xylazine has been thought to be primarily a problem in the Northeast region of the country. In patient samples submitted to Aegis for…

  8. Aegis Sciences Corporation Acquires HealthTrackRx’s Toxicology Business Unit

                                                                               Acquisition enhances Aegis’s toxicology portfolio, while HealthTrackRx expands…

                                                                               Acquisition enhances Aegis’s toxicology portfolio, while HealthTrackRx expands its PCR infectious disease testing  NASHVILLE, TN, January 16, 2023 – Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced the completion of its acquisition of the HealthTrackRx Toxicology line…

  9. Aegis Sciences Corporation Provides Insights into Early Detection Methods of COVID-19 Variants

    In collaboration with Walgreens, data analysis examines more than 300,000 COVID-19 samples during Omicron surge NASHVILLE, Tenn., (Oct. 6, 2022) – A manuscript…

    In collaboration with Walgreens, data analysis examines more than 300,000 COVID-19 samples during Omicron surge NASHVILLE, Tenn., (Oct. 6, 2022) – A manuscript detailing an extensive analysis completed by Aegis Sciences Corporation and Walgreens was published in PLOS ONE this week. The manuscript, Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants,…

  10. Aegis Sciences Corporation Expands Testing for Novel Psychoactive Substances

     Industry-leading testing offers insight into drug patterns and facilitates informed care Aegis Sciences Corporation, today announced the expansion of…

     Industry-leading testing offers insight into drug patterns and facilitates informed care Aegis Sciences Corporation, today announced the expansion of their proprietary, industry-leading novel psychoactive substance (NPS) testing. The expansion incorporates a wider range of synthetic compounds and refines their current testing capacity, allowing Aegis to track new substances and stay on the forefront…